Globalworld globe
United Kingdom
North America
  • facebook
  • linkedin
Medical Developments International
  • Home
  • Products
    • Asthma & COPD
    • Penthrox
    • Medical Devices
    • Veterinary
  • About
    • Distributor Information
    • Careers
    • Associations
  • Investors/Media
    • Financial Reports
    • Board of Directors/Management
    • Corporate Governance
    • Media Centre
    • Diversity Policy
    • Share Trading Policy
  • Healthcare Professionals
  • Contact

News

Penthrox Launch in the UK and Pricing Approval for Ireland

Jan 27, 2016Mark EdwardsNews

27 January 2016

ASX ANNOUNCEMENT

Penthrox Launch in the UK and Pricing Approval for Ireland

Medical Developments International Limited (ASX: MVP) is delighted to announce that its fast acting, category leading non-narcotic analgesic, Penthrox, was launched in the UK by Galen Limited on 25 January 2016.

In addition to the launch in the UK, MVP is delighted to announce Penthrox has received full pricing reimbursement approval from the Irish Medicine?s Board, which is another significant achievement.

For more information please refer to the following link ASX Announcement_Penthrox Launch in the UK and Pricing Approval for Ireland

Contact Us

for information on our range of products

Find a distributor

in our global network

Investors

invest in a company with
innovative foresight

News

  • FY21 Half Year Report and Accounts

    26 February 2021 ASX ANNO...

  • MVP Completes $25m Placement

    14 December 2020 ASX ANNO...

  • EU Transition and Trading Update

    3 December 2020 ASX ANNOU...

Healthcare Professional Registration

Login to access healthcare professional resources



Remember Me


Forgot password? | Register

Medical Developments International

Address:
4 Caribbean Drive, Scoresby,
Victoria, 3179
Australia
Phone: +61 3 9547 1888
Email: mdi@medicaldev.com
ABN: 14 106 340 667
For Medical Enquiries:

Phone: 1800 PENTHROX (1800 736 847)
Email: medinf@medicaldev.com

Email Newsletter

Sign up to our newsletter to receive MDI corporate, investor  & media news.